A study identified racial and ethnic disparities in survival among newly diagnosed patients with childhood cancers in the U.S., with area-level socioeconomic status and health insurance contributing to these disparities.
Scientists at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute of The Ohio State University Comprehensive Cancer Center are studying tissues collected within hours of death to gather clues as to why certain cancers are able to spread and evolve.
Researchers at City of Hope showed that patients over 65 receiving chemotherapy experienced significantly fewer treatment-related side effects when a multidisciplinary team of experts analyzed each case and introduced personalized interventions.
According to results from the PROpel phase III trial, Lynparza (olaparib) in combination with abiraterone had a significant positive effect on radiographic progression-free survival versus standard-of-care abiraterone as a first-line treatment for men with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations.
Researchers from Yale Cancer Center identified the Cancer and Aging Research Group calculator as an effective tool in assessing chemotherapy toxicity probability in geriatric patients.
A pilot program developed by researchers at Yale Cancer Center offering next day access for oncologic consultation for patients showed reduced wait times for initial access to cancer care and increased patient satisfaction, according to a new report.
The phase III GEMSTONE-301 study demonstrated the efficacy and safety of the anti-PD-L1 antibody sugemalimab as consolidation therapy in patients with locally advanced/unresectable stage 3 non-small cell lung cancer without disease progression after concurrent or sequential chemoradiotherapy.
Results from a phase III trial demonstrated the clinical benefit of using PD-1 inhibitor Libtayo (cemiplimab), in combination with a physician’s choice of platinum-doublet chemotherapy, in the treatment of patients with locally advanced or metastatic non-small cell lung cancer, irrespective of histology and across all PD-L1 expression levels.
UCLA Jonsson Comprehensive Cancer Center researchers found that treating women with HER2 positive metastatic breast cancer with the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan (T-DXd) significantly mitigates disease progression, compared to the current standard of care, trastuzumab emtansine (T-DM1).
Results from the phase III KEYNOTE-826 trial demonstrate that Keytruda (pembrolizumab) plus chemotherapy with or without bevacizumab improved disease outcomes when compared to chemotherapy with or without bevacizumab as a first-line treatment of persistent, recurrent, or metastatic cervical cancer.